Search results for "CORT"

showing 10 items of 3558 documents

Influence of hydrocortisone on chick embryo retina development

1987

Treatment of chick embryos in ovo with hydrocortisone-21-phosphate (a single dose of 150 micrograms) caused a marked reduction of retinal thymidine kinase activity 24 h later. The inhibitory effect was highest (65-70%) in 8-10-day-old embryos and declined with age, disappearing after day 15. It was accompanied by a reduction in thickness of the retinal layers. Adrenocorticotropic hormone (ACTH) treatment (10 micrograms daily for 2 days) also produced an age-dependent inhibitory effect on retinal thymidine kinase, whereas treatment with a single dose of 200 micrograms of metopirone, a compound that prevents the 11 beta-hydroxylation of steroid molecules in the adrenal glands, impeded the dec…

medicine.medical_specialtyThymidine kinase activityanimal structuresHydrocortisoneInfluence of hydrocortisonemedicine.medical_treatmentChick EmbryoAdrenocorticotropic hormoneBiologyIn ovoThymidine KinaseBiochemistryRetinaCellular and Molecular Neurosciencechemistry.chemical_compoundAdrenocorticotropic HormoneInternal medicinemedicineAnimalsHydrocortisoneMetyraponeRetinalMetyraponeSteroid hormoneEndocrinologychemistryThymidine kinaseembryonic structuresmedicine.drug
researchProduct

Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-anal…

2019

Background & Aims: Risk for relapse after induction of remission with steroid therapy has been studied extensively in patients with autoimmune pancreatitis (AIP), but findings have been equivocal. We performed a systematic review and meta-analysis to estimate the relapse rate of AIP after initial remission after steroid treatment and to identify factors associated with relapse. Methods: Three reviewers searched MEDLINE, SCOPUS, and EMBASE until July 2018 to identify studies on rate of relapse of AIP after induction of remission with steroid therapy. A pooled estimate was calculated using the DerSimonian and Laird method for a random-effects model. This study was conducted in accordance …

medicine.medical_specialtyTime FactorsAutoimmune Pancreatitismedicine.medical_treatmentMEDLINEInflammation; Long-Term Outcome; Pancreas; Response To TreatmentSteroidlaw.invention03 medical and health sciences0302 clinical medicineMaintenance therapyRandomized controlled trialRecurrenceRisk FactorslawInternal medicinemedicineHumansPancreaIn patientGlucocorticoidsPancreasAutoimmune pancreatitisInflammationHepatologybusiness.industryRemission InductionResponse To TreatmentGastroenterologyLong-Term Outcomemedicine.diseaseSystematic review030220 oncology & carcinogenesisMeta-analysisChronic Disease030211 gastroenterology & hepatologybusinessFollow-Up StudiesClinical Gastroenterology and Hepatology
researchProduct

Regional cerebral blood flow (rCBF) changes following local brain compression in the cat.

1968

medicine.medical_specialtyTime FactorsClinical BiochemistryBlood PressureInternal medicineBrain compressionmedicinePressureAnimalsHomeostasisAnesthesiaBrain ConcussionCerebral CortexCATSbusiness.industryGeneral MedicineRespiration ArtificialCerebrovascular CirculationBlood pressuremedicine.anatomical_structureCerebral blood flowCerebral cortexIschemic Attack TransientRegional Blood FlowCerebrovascular CirculationCardiologyCatsbusinessHomeostasisScandinavian journal of clinical and laboratory investigation. Supplementum
researchProduct

Alterations of Neuromuscular Function After Prolonged Running, Cycling and Skiing Exercises

2004

It is well known that impairment of performance resulting from muscle fatigue differs according to the types of contraction involved, the muscular groups tested and the exercise duration/intensity. Depending on these variables, strength loss with fatigue can originate from several sites from the motor cortex through to contractile elements. This has been termed 'task dependency of muscle fatigue'. Only recently have studies focused on the origin of muscle fatigue after prolonged exercise lasting 30 minutes to several hours. Central fatigue has been shown to contribute to muscle fatigue during long-distance running by using different methods such as the twitch interpolation technique, the ra…

medicine.medical_specialtyTime FactorsContraction (grammar)Neuromuscular transmissionPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseElectromyographyNervous SystemRunningContractilityPhysical medicine and rehabilitationSkiingmedicineHumansOrthopedics and Sports MedicineMuscle fatiguemedicine.diagnostic_testElectromyographybusiness.industryBicyclingBiomechanical PhenomenaPeripheralmedicine.anatomical_structureMuscle FatiguePhysical therapybusinessMotor cortexSports Medicine
researchProduct

Corticotropin-Releasing Hormone-Mediated Induction of Intracellular Signaling Pathways and Brain-Derived Neurotrophic Factor Expression Is Inhibited …

2005

CRH receptor (CRHR) 1 and the cannabinoid receptor 1 (CB1) are both G protein-coupled receptors. Activation of CRHR1 leadstoincreasesincAMPproductionandphosphorylationof the transcription factor cAMP response element-binding protein (CREB). In contrast, CB1 is negatively coupled to the cAMP signaling cascade. In this study, we analyzed a putative interaction between these two systems focusing on the regulation of the expression of brain-derived neurotrophic factor (BDNF), a CREB-regulated gene. In situ hybridization revealed coexpression of CRHR1 and CB1 receptors in the granular layer of the cerebellum. Therefore, we analyzed the effects of CRH and the CB1 agonist WIN-55,212-2 on BDNF expr…

medicine.medical_specialtyTime FactorsCorticotropin-Releasing HormoneMorpholinesmedicine.medical_treatmentImmunoblottingEnzyme-Linked Immunosorbent AssayTropomyosin receptor kinase BNaphthalenesCREBModels BiologicalRats Sprague-DawleyMiceEndocrinologyNeurotrophic factorsCerebellumInternal medicineCannabinoid Receptor ModulatorsCyclic AMPmedicineAnimalsRNA MessengerCyclic AMP Response Element-Binding ProteinReceptorEgtazic AcidCells CulturedIn Situ HybridizationNeuronsBrain-derived neurotrophic factorSulfonamidesbiologyReverse Transcriptase Polymerase Chain ReactionBrain-Derived Neurotrophic FactorCalcium Channel BlockersIsoquinolinesEndocannabinoid systemBenzoxazinesRatsMice Inbred C57BLPyrimidinesEndocrinologynervous systembiology.proteinCalciumCannabinoidSignal transductionEndocannabinoidsProtein BindingSignal TransductionEndocrinology
researchProduct

Influence of long-term postmenopausal hormone-replacement therapy on estimated structural bone strength: A study in discordant monozygotic twins

2010

Although postmenopausal hormone-replacement therapy (HRT) is known to prevent fractures, knowledge on the influence of long-term HRT on bone strength and its determinants other than areal bone mineral density is scarce. This study used a genetically controlled design with 24 monozygotic female twin pairs aged 54 to 72 years in which one cotwin was using HRT (mean duration 8 years) and the other had never used HRT. Estimated bone strength, cross-sectional area, volumetric bone mineral density, bone mineral mass, and cross-sectional density and mass distributions were assessed in the tibial shaft, distal tibia, and distal radius with peripheral computed tomography (pQCT). In the tibial shaft,…

medicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentDentistryMonozygotic twin030209 endocrinology & metabolismBone and Bones03 medical and health sciences0302 clinical medicineBone strengthBone DensitymedicineHumansPostmenopausal Hormone Replacement TherapyOrthopedics and Sports Medicineta315Aged030304 developmental biologyBone mineral0303 health sciencesPostmenopausal womenAnthropometrybusiness.industryEstrogen Replacement Therapyta3141Hormone replacement therapy (menopause)Organ SizeTwins Monozygoticta3142Middle AgedHormonesConfidence intervalSurgerymedicine.anatomical_structureBody CompositionFemaleCortical boneDiaphysesSelf ReportbusinessJournal of Bone and Mineral Research
researchProduct

Selective muscle hypertrophy, changes in EMG and force, and serum hormones during strength training in older women.

2001

Effects of strength training (ST) for 21 wk were examined in 10 older women (64 ± 3 yr). Electromyogram, maximal isometric force, one-repetition maximum strength, and rate of force development of the leg extensors, muscle cross-sectional area (CSA) of the quadriceps femoris (QF) and of vastus lateralis (VL), medialis (VM), intermedius (VI) and rectus femoris (RF) throughout the lengths of 3/12–12/15 (Lf) of the femur, muscle fiber proportion and areas of types I, IIa, and IIb of the VL were evaluated. Serum hormone concentrations of testosterone, growth hormone (GH), cortisol, and IGF-I were analyzed for the resting, preexercise, and postexercise conditions. After the 21-wk ST, maximal for…

medicine.medical_specialtyTime FactorsHydrocortisonePhysiologyStrength trainingBody heightMuscle Fibers SkeletalElectromyographyIsometric exerciseMuscle hypertrophyRate of force developmentPhysiology (medical)Internal medicineIsometric ContractionSex Hormone-Binding GlobulinmedicineHumansTestosteroneExercise physiologyInsulin-Like Growth Factor IMuscle SkeletalExerciseSerum hormonesAgedmedicine.diagnostic_testbusiness.industryElectromyographyHuman Growth HormoneBody WeightHypertrophyMiddle AgedBody HeightEndocrinologyPhysical FitnessFemalebusinessJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

The nicotinic acetylcholine receptor agonist (±)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain

2000

Abstract In a previous work, we showed that acute intermittent nicotine treatment up-regulates the level of fibroblast growth factor-2 (FGF-2) mRNA in brain regions of tel- and mesencephalon of rats suggesting that neuroprotective effect of (−)nicotine may, at least in part, involve an activation of the neuronal FGF-2 signalling. The present experiments were designed to extend the study on the nicotinic receptor mediated up-regulation of FGF-2 mRNA levels to the use of the potent nicotinic acetylcholine receptor (nAChR) agonist (±)-epibatidine. The (±)-epibatidine treatment led to a strong and long lasting up-regulation of FGF-2 mRNA expression in the cerebral cortex, in the hippocampal for…

medicine.medical_specialtyTime FactorsNicotinic acetylcoline receptor agonistPyridinesBlotting WesternNerve Tissue ProteinsNicotinic AntagonistsFibroblast growth factor-2MecamylamineBiologyHippocampusRats Sprague-DawleyNicotineCellular and Molecular NeuroscienceInternal medicineMecamylaminemedicineGlial cell line-derived neurotrophic factorAnimalsGlial Cell Line-Derived Neurotrophic FactorNerve Growth FactorsNicotinic AgonistsRNA MessengerMolecular BiologyIn Situ HybridizationEpibatidineCerebral CortexBrain-derived neurotrophic factorDose-Response Relationship DrugBrain-Derived Neurotrophic FactorBrainBridged Bicyclo Compounds HeterocyclicCorpus StriatumRatsSpecific Pathogen-Free OrganismsNicotinic acetylcholine receptorEndocrinologyNicotinic agonistGene Expression RegulationEpibatidinebiology.proteinFibroblast Growth Factor 2Alpha-4 beta-2 nicotinic receptorFibroblast growth factor receptor-1medicine.drugMolecular Brain Research
researchProduct

Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.

2011

Introduction: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, desmoglein-1 and -3. Before the advent of corticosteroids, therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to similar to 10%, but long-term use of steroids can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the patient's cumulative exposure to systemic corticosteroids. Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have …

medicine.medical_specialtyToxicologyMycophenolateMycophenolic acidPharmacokineticsAdrenal Cortex HormonesmedicineInitial treatmentimmunosuppressant inosine monophosphate dehydrogenase mycophenolate mofetil mycophenolic acid pemphigus pharmacokinetic treatmentHumansPharmacologyintegumentary systembusiness.industryMortality rateAutoantibodyGeneral MedicineMycophenolic Acidmedicine.diseaseDermatologyPemphigusImmunologybusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering diseaseExpert opinion on drug metabolismtoxicology
researchProduct